Holen Sie sich die Stockscreener-App
0.744
15.89%
0.102
Vorhandelsmarkt:
.70
-0.044
-5.91%
Schlusskurs vom Vortag:
$0.642
Offen:
$0.7172
24-Stunden-Volumen:
3.73M
Relative Volume:
11.68
Marktkapitalisierung:
$6.31M
Einnahmen:
$11.42M
Nettoeinkommen (Verlust:
$-2.89M
KGV:
-1.9528
EPS:
-0.381
Netto-Cashflow:
$-1.38M
1W Leistung:
+25.11%
1M Leistung:
+8.60%
6M Leistung:
-73.24%
1J Leistung:
-70.71%
1-Tages-Spanne:
$0.6543
$0.86
1-Wochen-Bereich:
$0.5901
$0.86
52-Wochen-Spanne:
$0.56
$2.968
Nexgel Inc Stock (NXGL) Company Profile
Firmenname
Nexgel Inc
Sektor
Telefon
215 702-8550
Adresse
2150 CABOT BLVD WEST,, LANGHORNE
Compare NXGL vs ISRG, BDX, MDLN, ALC, RMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NXGL
Nexgel Inc
|
0.744 | 6.31M | 11.42M | -2.89M | -1.38M | -0.381 |
ISRG
Intuitive Surgical Inc
|
451.29 | 160.28B | 10.06B | 2.88B | 2.49B | 7.876 |
BDX
Becton Dickinson Co
|
156.69 | 44.57B | 21.92B | 1.76B | 2.63B | 6.1223 |
MDLN
Medline Inc
|
47.51 | 38.56B | 28.43B | 1.16B | 1.26B | 1.4457 |
ALC
Alcon Inc
|
77.82 | 37.93B | 10.40B | 980.00M | 1.61B | 1.9749 |
RMD
Resmed Inc
|
221.22 | 32.23B | 5.40B | 1.49B | 1.78B | 10.12 |
Nexgel Inc Aktie (NXGL) Neueste Nachrichten
NEXGEL expects pro forma annual revenue of roughly $35M following Celularity wound segment acquisition - MSN
Celularity Announces Closing of Transaction with NexGel - Investing News Network
NXGL: Acquisition triples revenue and accelerates profitability, transforming the business platform - TradingView
Nexgel Inc co and Celularity enter amendment no. 1 to license agreement on April 17, 2026 - marketscreener.com
NEXGEL Secures Strategic Financing and Regenerative Portfolio License - TipRanks
NEXGEL (NASDAQ: NXGL) triples revenue outlook with Celularity deal, $6.9M notes - Stock Titan
Celularity Inc. announced that it has received $13.3 million in funding from NEXGEL, Inc. - marketscreener.com
Celularity Closes $13.3 Million Asset Sale to NexGel, Strengthening Focus on Longevity Therapeutics and Balance Sheet 1 - Minichart
Nexgel new strategic partner, Sequence LifeScience, leads financing with $5.5 million to complete acquisition of Celularity degenerative disease segment - marketscreener.com
Celularity Closes NexGel Asset Sale, Refocuses on Cell Therapy - TipRanks
NEXGEL closes Celularity biomaterials deal, raises $5.5 million - Investing.com
Biomaterials company Nexgel announces a key partnership with new strategic partner Sequence Lifescience™ - Bitget
Celularity (NASDAQ: CELU) closes NexGel asset sale as Helena note default looms - Stock Titan
A $5.5M financing gives NEXGEL 6 regenerative products and a new unit - Stock Titan
Celularity sells biomaterials assets, cuts nearly $13M of debt - Stock Titan
NexGel Inc stock (US65340W1027): Is its hydrogel tech edge strong enough for medtech growth? - AD HOC NEWS
NEXGEL reschedules shareholder call, revises financing plan - MSN
NexGel Inc stock (US65340W1027): Why its hydrogel tech edge matter more now for specialized medical - AD HOC NEWS
NEXGEL (NXGL) price target decreased by 66.67% to 2.04 - MSN
NEXGEL Moves Forward Shareholder Update Call to Discuss Celularity Transaction on April 21st at 4:30 P.M. ET - The Manila Times
Shareholders get NEXGEL's Celularity transaction update 2 days earlier - Stock Titan
NEXGEL signs agreement to acquire regenerative biomaterial portfolio - MSN
NEXGEL Reschedules Shareholder Update Call to April 23 - National Today
NEXGEL Reschedules Shareholder Update Conference Call to April 23rd at 4:30 P.M. ET to Provide Update on Celularity Transaction - The Manila Times
NEXGEL drops prior Celularity financing plan, sets April 23 update - Stock Titan
The Trade Desk (TTD) Shares Skyrocket, What You Need To Know - Barchart.com
NXGL Stock: NEXGEL Signs Deal to Triple Revenue and Turn Profitable With Acquisition of Six Commercial-Stage Regenerative Biomaterial Products - Barchart.com
NEXGEL Reschedules Shareholder Call, Revises Financing Plan - MyChesCo
3 Reasons to Avoid FTRE and 1 Stock to Buy Instead - Barchart.com
Pharma News: Should you avoid NEXGEL Inc stock right now2026 EndofYear Setup & Verified Swing Trading Watchlists - baoquankhu1.vn
Momentum Shift: Is NEXGEL Inc Equity Warrant benefiting from innovation trends2026 Sector Review & Momentum Based Trading Signals - baoquankhu1.vn
2 High-Flying Stocks with Exciting Potential and 1 We Ignore - Barchart.com
NexGel Inc stock (US65340W1027): Is its hydrogel innovation strong enough to drive U.S. medical grow - AD HOC NEWS
AUDUSD Update: Breaking Higher Following Completion of Corrective Structure - Barchart.com
Stocks in play: Seabridge Gold Inc. - Barchart.com
AI Stocks: Will NEXGEL Inc benefit from rising consumer demandMarket Growth Review & Daily Price Action Insights - baoquankhu1.vn
TEST TEST TEST - Barchart.com
Sectors Review: Is NEXGEL Inc stock a good pick for beginners2026 Setups & Daily Technical Forecast Reports - baoquankhu1.vn
NEXGEL Reschedules Shareholder Update Conference Call to April 15th at 4:30 P.M. ET to Provide Update on Celularity Transaction - The Manila Times
Analyst Calls: Should you avoid NEXGEL Inc stock right now2026 Trade Ideas & Consistent Profit Focused Trading Strategies - baoquankhu1.vn
NexGel Inc (NXGL) Q4 2025 Earnings Call Highlights: Strong Revenue Growth Amid Operational ... By GuruFocus - Investing.com Canada
3 Reasons to Avoid AIT and 1 Stock to Buy Instead - Barchart.com
3 Reasons to Avoid INGR and 1 Stock to Buy Instead - Barchart.com
NexGel Inc stock: Acquisition Deal to Triple Revenue Sparks Investor Interest - AD HOC NEWS
NVR's Quarterly Earnings Preview: What You Need to Know - Barchart
Sentiment Watch: Is NEXGEL Inc attractive for institutional investors2026 Short Interest & Safe Entry Momentum Tips - baoquankhu1.vn
Here's What to Expect From 3M Company's Next Earnings Report - Barchart.com
Nexgel earnings missed by $0.09, revenue fell short of estimates - Investing.com Canada
Exclusive: NexGel to acquire regenerative biomaterial portfolio from Celularity, expects to triple revenue - MSN
3 Reasons to Sell RMAX and 1 Stock to Buy Instead - Barchart.com
Fed Watch: Is NEXGEL Inc Equity Warrant still a buy after recent gains - baoquankhu1.vn
Finanzdaten der Nexgel Inc-Aktie (NXGL)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.86%
1.85%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):